Acute Kidney Injury With RIPE Tuberculosis Therapy
RIPE (rifampin, isoniazid, pyrazinamide, ethambutol) can be associated with acute kidney injury (AKI), but AKI is generally uncommon in anti-tuberculosis treatment. [1]
Rifampin has reported renal toxicity patterns, including rifampin-associated AKI that can recur with re-exposure and can be linked to hypersensitivity-type mechanisms. [2] [3]
Rifampin Dose Considerations for AKI Risk
Standard adult rifampin dosing for tuberculosis is 10 mg/kg once daily with a maximum of 600 mg/day. [4] [5]
A rifampin dose of 1200 mg/day is above the labeled maximum daily dose for tuberculosis dosing. [4]
Rifampin renal hypersensitivity reactions have been reported with interruption and subsequent resumption of therapy. [6] [7]
Drug-Specific AKI Mechanisms Relevant to RIPE
Rifampin-associated AKI has been described with clinical and laboratory features compatible with hypersensitivity or immune-mediated renal injury patterns. [2] [8]
Rifampin has also been described as capable of causing acute interstitial nephritis. Rifampicin monograph (ouh.quris.com)
Clinical Pattern Distinguishing AKI From RIPE vs Intercurrent Illness
Severe systemic illness, shock, dehydration, and concurrent nephrotoxic exposures are common contributors to AKI during tuberculosis treatment and may confound attribution to RIPE drugs. [1] [9]
In reported rifampin-associated AKI cases, recurrence after re-exposure supports a causal relationship rather than coincidence. [2] [8]
AKI Monitoring and Immediate Evaluation
AKI during RIPE should prompt review for prerenal causes (volume depletion, hypotension) and medication-related contributors, including rifampin-associated hypersensitivity patterns. [1] [9]
Rifampin-associated AKI should be specifically considered when AKI temporally follows rifampin initiation or rifampin re-start after interruption. [10] [3]
Practical Interpretation of “Does RIPE Cause AKI?”
RIPE is capable of causing AKI, including rifampin-related renal injury. [2] [8]
AKI is rare in anti-tuberculosis therapy overall, so alternative AKI causes often coexist. [1] [9]
Rifampin dosing of 1200 mg daily exceeds labeled maximum dosing for tuberculosis, which increases concern for toxicity and should trigger immediate dosing review. [4] [5]